Table 2.
Treatment characteristics and clinical outcomes.
| Characteristic | Whole cohort (n = 204) |
L-PIV (n = 75) |
H-PIV (n = 129) |
P value |
|---|---|---|---|---|
| Adjuvant TMZ cycles, n (%) | ||||
| 1-6 | 84 (41.2) | 33 (44.0) | 51 (39.5) | 0.32 |
| 7-12 | 120 (58.8) | 42 (56.0) | 78 (60.5) | |
| Brain failure, n (%) | ||||
| Absent | 14 (6.9) | 12 (16.0) | 2 (1.6) | 0.02 |
| Present | 190 (93.1) | 63 (84.0) | 127 (98.4) | |
| Brain failure type, n (%) | ||||
| None | 14 (6.9) | 12 (16.0) | 2 (1.6) | 0.19 |
| Infield | 164 (80.4) | 56 (74.6) | 108 (83.7) | |
| Marginal | 16 (7.7) | 5 (6.7) | 11 (8.5) | |
| Distant | 4 (1.9) | 0 (0) | 4 (3.1) | |
| Infield and distant | 5 (2.6) | 2 (2.7) | 3 (2.3) | |
| Marginal and distant | 1 (0.5) | 0 (0) | 1 (0.8) | |
| Salvage treatment, n (%) | ||||
| Absent | 71 (34.8) | 27 (36.0) | 44 (34.1) | 0.91 |
| Present | 133 (65.2) | 48 (64.0) | 85 (65.9) | |
| Salvage treatment, n (%) | ||||
| None | 71 (34.8) | 27 (36.0) | 44 (34.1) | 0.57 |
| BEVIRI | 38 (18.7) | 14 (18.7) | 24 (18.6) | |
| RO | 17 (8.3) | 7 (9.3) | 10 (7.8) | |
| SRS/SRT | 17 (8.3) | 6 (8.0) | 11 (8.5) | |
| RO + SRS/SRT | 16 (7.8) | 6 (8.0) | 10 (7.8) | |
| RO + BEVIRI | 19 (9.4) | 6 (8.0) | 13 (10.0) | |
| RO + SRS + BEVIRI | 17 (8.3) | 6 (8.0) | 11 (8.5) | |
| Unknown | 9 (4.4) | 3 (4.0) | 6 (4.7) | |
| Progression-free survival | ||||
| Median, mo. (95% CI) | 10.3 (7.8-131) | 17.4 (13.3-21.4) | 7.3 (5.3-9.3) | <0.001 |
| 1-year, % | 48.2 | 69.0 | 36.0 | 0.007 |
| 3-year, % | 10.8 | 25.6 | 2.4 | <0.001 |
| 5-year, % | 6.4 | 18.0 | 0 | <0.001 |
| Overall survival | ||||
| Median, mo. (95% CI) | 15.8 (13.0-18.6) | 24.9 (22.0-27.8) | 12.4 (10.5-14.2) | <0.001 |
| 1-year, % | 63.9 | 82.5 | 53.1 | 0.003 |
| 3- year, % | 11.8 | 25.6 | 4.2 | <0.001 |
| 5-year, % | 7.3 | 20.8 | 0 | <0.001 |
Abbreviations: L-PIV: low pan-immune-inflammation value; H-PIV: high pan-immune-inflammation value; TMZ: temozolomide; BEVIRI: bevacizumab plus irinotecan; RO: reoperation; SRS/SRT: stereotactic radiosurgery/stereotactic radiotherapy.